Compare TNK & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNK | SLS |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.1B |
| IPO Year | 2007 | 2007 |
| Metric | TNK | SLS |
|---|---|---|
| Price | $99.52 | $11.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $96.80 | $32.50 |
| AVG Volume (30 Days) | 354.5K | ★ 5.0M |
| Earning Date | 11-06-2026 | 11-11-2026 |
| Dividend Yield | ★ 1.05% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.17 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.05 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $50.94 | $1.39 |
| 52 Week High | $110.65 | $15.88 |
| Indicator | TNK | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 53.35 | 48.42 |
| Support Level | $71.28 | $10.78 |
| Resistance Level | $103.16 | $12.62 |
| Average True Range (ATR) | 3.61 | 0.85 |
| MACD | -1.03 | 0.05 |
| Stochastic Oscillator | 37.85 | 58.58 |
Teekay Tankers Ltd is a provider of marine services to the international oil and natural gas industries and an operator of medium-sized oil tankers. The company operates in two segments: Tankers, which consists of the operation of all of the company's tankers (including the operations from those tankers employed on full service lightering contracts), and the company's U.S. based ship-to-ship support service operations (including its lightering support services provided as part of full service lightering operations); and Marine Services, which consists of operational and maintenance marine services provided to the Australian government, Australian energy companies and other third parties. The company generates the majority of its revenue from the Tankers segment.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.